找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cytokine Frontiers; Regulation of Immune Takayuki Yoshimoto,Tomohiro Yoshimoto Book 2014 Springer Japan 2014 Anti-inflammatory cytokines.Pr

[復制鏈接]
查看: 37570|回復: 53
樓主
發(fā)表于 2025-3-21 17:44:44 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cytokine Frontiers
副標題Regulation of Immune
編輯Takayuki Yoshimoto,Tomohiro Yoshimoto
視頻videohttp://file.papertrans.cn/243/242628/242628.mp4
概述Includes supplementary material:
圖書封面Titlebook: Cytokine Frontiers; Regulation of Immune Takayuki Yoshimoto,Tomohiro Yoshimoto Book 2014 Springer Japan 2014 Anti-inflammatory cytokines.Pr
描述.This book guides the reader through the latest research on the cytokine network, covering signaling pathways, control of the immune response, and potential therapeutics. Different cytokines stimulate diverse responses in various phases of inflammation and immunity, including the innate immune response, the generation of effector T cells, and the development of antibodies by the humoral immune system. It is now clear that the pathophysiology of many infectious, autoimmune, allergic, and malignant diseases can be largely explained by which cytokines are induced and subsequently regulate the cellular responses. In clinical medicine, cytokines are involved in a wide spectrum of diseases. This book describes in three parts the properties and roles of 15 key cytokines under physiological and pathological conditions. Part I presents nine cytokines associated with inflammatory disorders, pro-inflammatory cytokines, and the recently identified new helper T (Th) subset: Th17 cells. Part II gives details of three cytokines associated with allergic disorders, including Th2 responses and recently identified types of innate cells. Part III describes three cytokines that are associated with immu
出版日期Book 2014
關鍵詞Anti-inflammatory cytokines; Pro-inflammatory cytokines; Th2-type cytokines
版次1
doihttps://doi.org/10.1007/978-4-431-54442-5
isbn_softcover978-4-431-56124-8
isbn_ebook978-4-431-54442-5
copyrightSpringer Japan 2014
The information of publication is updating

書目名稱Cytokine Frontiers影響因子(影響力)




書目名稱Cytokine Frontiers影響因子(影響力)學科排名




書目名稱Cytokine Frontiers網(wǎng)絡公開度




書目名稱Cytokine Frontiers網(wǎng)絡公開度學科排名




書目名稱Cytokine Frontiers被引頻次




書目名稱Cytokine Frontiers被引頻次學科排名




書目名稱Cytokine Frontiers年度引用




書目名稱Cytokine Frontiers年度引用學科排名




書目名稱Cytokine Frontiers讀者反饋




書目名稱Cytokine Frontiers讀者反饋學科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 21:32:52 | 只看該作者
板凳
發(fā)表于 2025-3-22 04:18:58 | 只看該作者
The Roles of IL-17A and IL-17F in Infection and Inflammatory Disorders17A among the IL-17 family and binds to the same IL-17 receptor A (IL-17RA) and IL-17RC receptor complex as IL-17A. Recent studies have demonstrated that IL-17A and IL-17F are also produced by multiple lineages of immune cells, including γδ T cells, NKT cells, and innate lymphoid cells. These cytoki
地板
發(fā)表于 2025-3-22 05:33:58 | 只看該作者
5#
發(fā)表于 2025-3-22 09:48:22 | 只看該作者
6#
發(fā)表于 2025-3-22 14:41:07 | 只看該作者
Interleukin-22: A Bridge Between Epithelial Innate Host Defense and Immune Cellsipheral tissue epithelial cells. IL-22 functions as a unique messenger from immune system to tissue epithelial cells and to regulate homeostasis of epithelia. IL-22 is able to directly enhance antimicrobial defense mechanisms in epithelial cells and to facilitate epithelial barrier repair and wound
7#
發(fā)表于 2025-3-22 20:04:09 | 只看該作者
8#
發(fā)表于 2025-3-23 00:47:34 | 只看該作者
IL-36: An Epithelial Cytokine Important in Psoriasisby epithelial tissues. Similar to other IL-1 family cytokines, they promote inflammatory responses by activating kinases such as JNK, p38, and the IKKs, and activating transcription factors such as NFκB. They only do this, however, after N-terminal processing, which increases their specific activity
9#
發(fā)表于 2025-3-23 04:35:07 | 只看該作者
Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventuredisease tissue in rheumatoid arthritis and on exploring the dysregulation of cytokine expression within that tissue..From those first successful clinical trials we conducted in 1992 with infliximab, which were widely publicized more than a year before publication, a competition emerged between a set
10#
發(fā)表于 2025-3-23 09:29:12 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 14:12
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
大兴区| 安阳县| 北流市| 施秉县| 大埔县| 泸州市| 西贡区| 鄄城县| 崇明县| 峡江县| 翼城县| 格尔木市| 呼玛县| 克东县| 元江| 思茅市| 铜陵市| 丰台区| 自贡市| 铁力市| 定结县| 中方县| 浮山县| 永春县| 彭阳县| 满城县| 十堰市| 民丰县| 乌拉特前旗| 襄汾县| 凤阳县| 曲阜市| 翼城县| 东至县| 红河县| 鸡东县| 富阳市| 湖南省| 望都县| 寿光市| 明水县|